Journal article

Immunosuppressive strategies in invasively ventilated ARDS COVID-19 patients

Giacomo Monti, Corrado Campochiaro, Alberto Zangrillo, Anna M Scandroglio, Evgeny Fominskiy, Giulio Cavalli, Giovanni Landoni, Luigi Beretta, Milena Mucci, Maria G Calabro, Marina Pieri, Pasquale Nardelli, Marianna Sartorelli, Martina Baiardo Redaelli, Federica Morselli, Ary Serpa Neto, Rinaldo Bellomo, Lorenzo Dagna

MINERVA ANESTESIOLOGICA | EDIZIONI MINERVA MEDICA | Published : 2021

Abstract

BACKGROUND: COVID-19 is associated with elevated levels of inflammatory cytokines. We present the characteristics and outcomes of patients treated in the Intensive Care Unit (ICU) with immunosuppressive drugs, either tocilizumab or anakinra compared with controls. METHODS: A single-center observational prospective study on ICU invasively ventilated COVID-19 patients. The primary outcome was the clinical improvement at day 28. A Bayesian framework was employed, and all analyses were adjusted for confounders. RESULTS: Sixty-one consecutive invasively ventilated patients were included, nine (14.7%) received tocilizumab and 15 (24.6%) received anakinra. Over the first seven days, tocilizumab was..

View full abstract

University of Melbourne Researchers